[A14-34] Dolutegravir/abacavir/lamivudine - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Last updated 02.01.2015
Project no.:
A14-34
Commission:
Commission awarded on 12.09.2014 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-11 | Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A14-08 | Dolutegravir - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A23-17 | Dolutegravir/abacavir/lamivudine (HIV infection in children) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2015-03-19 A G-BA decision was published.